BB Biotech is trading at a share price of CHF 36.9 compared to a net asset value per share of CHF 40.5, reflecting an 8.8% discount (vs. avg. 3% discount LTM and 11.4% premium in the last five years). The current head of Investment Management, Dr. Daniel Koller, will retire from his position and deputy head, Dr. Christian Koch, will take over at the beginning of 2025.

https://research.sebgroup.com/corporate/reports/129616

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.